Polysaccharides, especially those derived from medicinal mushrooms (such as Ganoderma lucidum and Coriolus versicolor) and plants (like Lycium barbarum), have been investigated for their potential hepatoprotective and immunomodulatory effects in the context of hepatitis. Multiple preclinical studies (in vitro and animal models) suggest that certain polysaccharides can exert antiviral effects against hepatitis viruses, modulate immune responses, and reduce liver inflammation or fibrosis. For example, research published in journals such as International Journal of Biological Macromolecules and Phytotherapy Research indicates that some polysaccharides can inhibit hepatitis B virus (HBV) replication and improve liver enzyme profiles in animal models. Additionally, clinical studies—though generally small and of variable quality—have reported improvements in liver function tests and patient-reported symptoms in hepatitis B and C patients using polysaccharide-rich extracts as adjuncts to conventional treatment.

However, robust, large-scale randomized controlled trials in humans are lacking, and most evidence comes from experimental models or preliminary clinical trials. Thus, while the use of polysaccharides to support hepatitis treatment is justified by a growing body of scientific research, the overall quality and quantity of evidence remain modest, and definitive clinical recommendations cannot yet be made. Use of these compounds should be considered experimental and adjunctive, not a replacement for established antiviral therapies.